AURA Stock Analysis: Buy, Sell, or Hold?
AURA - Aura Biosciences, Inc. Common Stock
$6.69
0.49 (7.90%)
▲
5d:
+6.02%
30d:
+8.96%
90d:
+22.53%
BUY
MODERATE Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 07, 2026
Get Alerted When AURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AURA is currently trading at $6.69, which is considered extended relative to its 30-day fair value range of $5.76 to $6.53.
Technical Outlook: Technically, AURA is in a uptrend. The price is approaching resistance at $6.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.20 (+201.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AURA is in a uptrend. The price is approaching resistance at $6.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.20 (+201.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$5.76 -
$6.53
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.9%)
- BULLISH: Trading 201.9% below Wall St target ($20.20)
Fair Price Analysis
30-Day Fair Range
$5.76 -
$6.53
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.85
(12.7%)
Support & Resistance Levels
Support Level
$6.17
Resistance Level
$6.83
Current Trend
Uptrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.75
Wall Street Target
$20.20
(+201.9%)
Share & Embed Analysis
Last updated: April 01, 2026 1:17 AM ET
Data refreshes hourly during market hours. Next update: 2:17 AM
Data refreshes hourly during market hours. Next update: 2:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AURA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Conor Kilroy
SELL
12079 shares
2026-02-17
Janet Jill Hopkins
SELL
20401 shares
2026-02-17
Los Pinos Elisabet De
SELL
47648 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 66 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 BUY |
